Abstract OT2-09-01: Pilot study of denosumab in BRCA1/2 mutation carriers scheduling for risk-reducing salpingo-oophorectomy

Autor: M House, RM Wenham, Goli Samimi, Howard L. Parnes, J. Jack Lee, Judy Garber, PH Brown, Jason D. Wright, Lana Vornik, S Abutaseh, Neil S. Horowitz, Katherine D. Crew, Trivedi, K Holcomb, Brandy M. Heckman-Stoddard, Eitan Friedman, N Arber

Publikováno v: Cancer Research. 79:OT2-09

Background: Denosumab is a monoclonal antibody that inhibits RANKL and is approved for the prevention of fractures in patients with osteoporosis or bone metastases. The RANKL signaling pathway is also involved in BRCA1-associated mammary tumorigenesi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e86f4ac314983a4b2d18151e010a6765
https://doi.org/10.1158/1538-7445.sabcs18-ot2-09-01

Post-traumatic reactions and quality of life after pelvic exenteration for gynecologic cancer: a retrospective cohort study.

Autor: Thompson LMA; Department of Supportive Care Medicine, Moffitt Cancer Center, Tampa, FL, USA., Loecher N; St. Jude Children's Research Hospital, Memphis, TN, USA.; College of Behavioral and Community Sciences, University of South Florida, Tampa, FL, USA., Albizu-Jacob A; College of Behavioral and Community Sciences, University of South Florida, Tampa, FL, USA., Chon HS; Department of Gynecologic Oncology, Moffitt Cancer Center, Tampa, FL, USA., Wenham RM; Department of Gynecologic Oncology, Moffitt Cancer Center, Tampa, FL, USA., Donovan KA; Department of Psychiatry and Psychology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. donovan.kristine@mayo.edu.

Publikováno v: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2024 Oct 15; Vol. 32 (11), pp. 729. Date of Electronic Publication: 2024 Oct 15.

A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.

Autor: Liu JF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America. Electronic address: joyce_liu@dfci.harvard.edu., Xiong N; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, United States of America., Wenham RM; Department of Gynecologic Oncology, Moffitt Cancer Center, Tampa, FL, United States of America., Wahner-Hendrickson A; Department of Medical Oncology, Mayo Clinic, Rochester, MN, United States of America., Armstrong DK; Department of Medical Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States of America., Chan N; Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, United States of America., O'Malley DM; Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH, United States of America., Lee JM; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States of America., Penson RT; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, United States of America., Cristea MC; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, United States of America., Abbruzzese JL; Department of Medical Oncology, Duke Cancer Institute, Durham, NC, United States of America., Matsuo K; Department of Obstetrics & Gynecology, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States of America., Olawaiye AB; Department of OBGYN, University of Pittsburgh Medical Center, Pittsburgh, PA, United States of America., Barry WT; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, United States of America., Cheng SC; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, United States of America., Polak M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America., Swisher EM; Department of Obstetrics & Gynecology, University of Washington, Seattle, WA, United States of America., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America., Kohn EC; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States of America; Clinical Investigations Branch, NCI Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, United States of America., Ivy SP; Investigational Drug Branch, NCI Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, United States of America., Matulonis UA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2024 Aug; Vol. 187, pp. 105-112. Date of Electronic Publication: 2024 May 17.

Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study.

Autor: Chan JK; California Pacific/Palo Alto Medical Foundation/Sutter Research Institute, San Francisco, CA, USA. Electronic address: chanjohn@sutterhealth.org., Tian C; NRG Statistical Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Kesterson JP; Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA. Electronic address: kestersonjp@upmc.edu., Lin KY; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Darcy K; NRG Statistical Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Electronic address: darcyk@whirc.org., Richardson MT; University of California, Los Angeles School of Medicine, Los Angeles, CA, USA. Electronic address: mtrichardson@mednet.ucla.edu., Kapp DS; Stanford University School of Medicine, Stanford, CA, USA. Electronic address: dskapp@stanford.edu., Monk BJ; HonorHealth Research Institute, University of Arizona, Creighton University, Phoenix, AZ, USA. Electronic address: bmonk@gog.org., McNally L; Duke University, Durham, NC, USA. Electronic address: leah.mcnally018@duke.edu., Landrum L; Indiana University, Indianapolis, IN, USA. Electronic address: llandru@iu.edu., Copeland L; Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. Electronic address: Larry.Copeland@osumc.edu., Walker JL; University of Oklahoma, Oklahoma City, OH, USA. Electronic address: joan-walker@ouhsc.edu., Wenham RM; Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address: Robert.wenham@moffitt.org., Phippen N; Walter Reed National Military Medical Center, Bethesda, MD, USA. Electronic address: neil.phippen@usuhs.edu., Spirtos NM; Womens Cancer Center of Nevada, Las Vegas, NV, USA. Electronic address: nmspirtos@wccenter.com., Tewari K; University of California Medical Center at Irvine, Irvine, CA, USA. Electronic address: ktewari@hs.uc.edu., Shahin M; Abington Memorial Hospital, Abington, PA, USA. Electronic address: Mark.Shahin@jefferson.edu., Berry L; Wake Forest University Health Sciences, Winston-Salem, NC, USA. Electronic address: lkberry@wakehealth.edu., Bell JG; Ohio Riverside Methodist Hospital, Columbus, OH, USA.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2024 Feb; Vol. 181, pp. 54-59. Date of Electronic Publication: 2023 Dec 21.

A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.

Autor: Han SN; Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Department of Oncology, KU Leuven, Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium. Electronic address: sileny.han@uzleuven.be., Oza A; Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Colombo N; Obstetrics and Gynaecology, University of Milano-Bicocca and European Institute of Oncology IRCCS, Milan, Italy., Oaknin A; Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Raspagliesi F; Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Wenham RM; Department of Gynecologic Oncology, Moffitt Cancer Center, Tampa, FL, USA., Braicu EI; Department for Gynecology Campus Virchow, Charité Medical University Berlin, Berlin, Germany., Jewell A; Obstetrics and Gynecology, University of Kansas Cancer Center, Kansas City, KS, USA., Makker V; Medical Oncology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Krell J; Department of Medical Oncology, Imperial College London, London, UK., Alía EMG; Medical Oncology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain., Baurain JF; Medical Oncology Department, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium., Su Z; Computational Biology, Takeda Development Center Americas, Inc., Lexington, MA, USA., Neuwirth R; Biostatistics, Takeda Development Center Americas, Inc., Lexington, MA, USA., Vincent S; Translational Medicine, Takeda Development Center Americas, Inc., Lexington, MA, USA., Sedarati F; Oncology Clinical Research, Takeda Development Center Americas, Inc., Lexington, MA, USA., Faller DV; Oncology Clinical Research, Takeda Development Center Americas, Inc., Lexington, MA, USA., Scambia G; Women, Children and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of the Sacred Heart School of Medicine, Rome, Italy.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2023 Nov; Vol. 178, pp. 110-118. Date of Electronic Publication: 2023 Oct 14.